Literature DB >> 21523772

Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer.

Mary-Clare Cathcart1, Steven G Gray, Anne-Marie Baird, Elaine Boyle, Kathy Gately, Elaine Kay, Robert Cummins, Graham P Pidgeon, Kenneth J O'Byrne.   

Abstract

BACKGROUND: Prostacyclin synthase (PGIS) metabolizes prostaglandin H(2), into prostacyclin. This study aimed to determine the expression profile of PGIS in nonsmall cell lung cancer (NSCLC) and examine potential mechanisms involved in PGIS regulation.
METHODS: PGIS expression was examined in human NSCLC and matched controls by reverse transcriptase polymerase chain reaction (RT-PCR), Western analysis, and immunohistochemistry. A 204-patient NSCLC tissue microarray was stained for PGIS and cyclooxygenase 2 (COX2) expression. Staining intensity was correlated with clinical parameters. Epigenetic mechanisms underpinning PGIS promoter expression were examined using RT-PCR, methylation-specific PCR, and chromatin immunoprecipitation analysis.
RESULTS: PGIS expression was reduced/absent in human NSCLC protein samples (P < .0001), but not mRNA relative to matched controls. PGIS tissue expression was higher in squamous cell carcinoma (P = .004) and in male patients (P < .05). No significant correlation of PGIS or COX2 expression with overall patient survival was observed, although COX2 was prognostic for short-term (2-year) survival (P < .001). PGIS mRNA expression was regulated by DNA CpG methylation and histone acetylation in NSCLC cell lines, with chromatin remodeling taking place directly at the PGIS gene. PGIS mRNA expression was increased by both demethylation agents and histone deacetylase inhibitors. Protein levels were unaffected by demethylation agents, whereas PGIS protein stability was negatively affected by histone deacetylase inhibitors.
CONCLUSIONS: PGIS protein expression is reduced in NSCLC, and does not correlate with overall patient survival. PGIS expression is regulated through epigenetic mechanisms. Differences in expression patterns between mRNA and protein levels suggest that PGIS expression and protein stability are regulated post-translationally. PGIS protein stability may have an important therapeutic role in NSCLC.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523772     DOI: 10.1002/cncr.26168

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Comprehensive analysis of tumor microenvironment and identification of an immune signature to predict the prognosis and immunotherapeutic response in lung squamous cell carcinoma.

Authors:  Jinlong Wu; Chengfeng Xu; Xin Guan; Da Ni; Xuhui Yang; Zhiyin Yang; Mingsong Wang
Journal:  Ann Transl Med       Date:  2021-04

2.  Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies.

Authors:  Marybeth Sechler; Amber D Cizmic; Sreedevi Avasarala; Michelle Van Scoyk; Christine Brzezinski; Nicole Kelley; Rama Kamesh Bikkavilli; Robert A Winn
Journal:  Pharmgenomics Pers Med       Date:  2013-04-04

3.  IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer.

Authors:  Anne-Marie Baird; Eilis Dockry; Anne Daly; Emma Stack; Derek G Doherty; Kenneth J O'Byrne; Steven G Gray
Journal:  Front Oncol       Date:  2013-06-19       Impact factor: 6.244

Review 4.  Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies.

Authors:  Rehana Yasmin; Sami Siraj; Amjad Hassan; Abdul Rehman Khan; Rashda Abbasi; Nafees Ahmad
Journal:  Mediators Inflamm       Date:  2015-03-01       Impact factor: 4.711

5.  miR-520a-5p regulates Frizzled 9 expression and mediates effects of cigarette smoke and iloprost chemoprevention.

Authors:  A J Smith; P Do; K Sompel; A Elango; M A Tennis
Journal:  Sci Rep       Date:  2022-02-11       Impact factor: 4.379

6.  Comprehensive molecular characterization of hypertension-related genes in cancer.

Authors:  Yanan Jiang; Chunpeng Shi; Songyu Tian; Fengnan Zhi; Xiuyun Shen; Desi Shang; Jinwei Tian
Journal:  Cardiooncology       Date:  2022-05-05

Review 7.  Perspectives on epigenetic-based immune intervention for rheumatic diseases.

Authors:  Steven G Gray
Journal:  Arthritis Res Ther       Date:  2013-03-14       Impact factor: 5.156

8.  A molecular signature for the prediction of recurrence in colorectal cancer.

Authors:  Lisha Wang; Xiaohan Shen; Zhimin Wang; Xiuying Xiao; Ping Wei; Qifeng Wang; Fei Ren; Yiqin Wang; Zebing Liu; Weiqi Sheng; Wei Huang; Xiaoyan Zhou; Xiang Du
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

9.  Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro.

Authors:  Thomas Klein; Jens Benders; Friederike Roth; Monika Baudler; Isabel Siegle; Martin Kömhoff
Journal:  Mediators Inflamm       Date:  2015-07-27       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.